Enforced expression of miR‑101 enhances cisplatin sensitivity in human bladder cancer cells by modulating the cyclooxygenase‑2 pathway

Bu,Qiang; Fang,Yue; Cao,Yuan; Chen,Qiaoyun; Liu,Yangchen

doi:10.3892/mmr.2014.2455

Enforced expression of miR‑101 enhances cisplatin sensitivity in human bladder cancer cells by modulating the cyclooxygenase‑2 pathway

Authors:
- Qiang Bu
- Yue Fang
- Yuan Cao
- Qiaoyun Chen
- Yangchen Liu
View Affiliations

Affiliations: Department of Urology, Danyang People's Hospital, Zhenjiang, Jiangsu, P.R. China, Department of Central Laboratory, The Affiliated People's Hospital, Jiangsu University, Zhenjiang, P.R. China, Department of Oncology, Taixing People's Hospital, Taixing, Jiangsu, P.R. China
Published online on: August 6, 2014 https://doi.org/10.3892/mmr.2014.2455
Pages: 2203-2209

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Alterations in microRNA (miRNA) expression have been shown to be involved in the tumor response to chemotherapy. However, the possible role of miR‑101 in cisplatin sensitivity in human bladder cancer cells remains unclear. In this study, quantitative polymerase chain reaction and western blotting were utilized to determine the expression profiles of miR‑101 and cyclooxygenase‑2 (COX‑2) in human bladder cancer cells. The effect of miR‑101 and small interfering RNA (siRNA) against COX‑2 on cell viability was evaluated using MTT assays, and apoptosis levels were determined using fluorescence‑activated cell sorting analysis of Annexin V/propidium iodide‑stained cells. Luciferase reporter plasmids were constructed to confirm direct targeting. This study found that the expression of miR‑101 was downregulated in the cisplatin‑resistant cell line T24/CDDP as compared with that in the parental line, T24. Furthermore, overexpression of miR‑101 significantly increased the anti‑proliferative effects and apoptosis induced by cisplatin, whereas knockdown of miR‑101 significantly decreased the anti‑proliferative effects and apoptosis induced by cisplatin. In addition, downregulation of miR‑101 induced cell survival and cisplatin resistance through the upregulation of COX‑2 expression. Luciferase gene reporter assays confirmed that COX‑2 was a direct target gene of miR‑101. Inhibition of COX‑2 using COX‑2 siRNA abrogated the cisplatin resistance induced by miR‑101 downregulation. These results suggest that miR‑101 may provide a novel mechanism for understanding cisplatin resistance in bladder cancer by modulating the COX‑2 pathway.

View Figures

View References

1	Bo J, Yang G, Huo K, et al: microRNA-203 suppresses bladder cancer development by repressing bcl-w expression. FEBS J. 278:786–792. 2011. View Article : Google Scholar : PubMed/NCBI
2	Donat SM: Integrating perioperative chemotherapy into the treatment of muscle-invasive bladder cancer: strategy versus reality. J Natl Compr Canc Netw. 7:40–47. 2009.
3	Kakizoe T, Mucci LA, Albertsen PC and Droller MJ: Screening for bladder cancer: theoretical and practical issues in considering the treated and untreated natural history of the various forms of the disease. Scand J Urol Nephrol Suppl. 191–212. 2008. View Article : Google Scholar
4	Noguchi S, Mori T, Hoshino Y, et al: MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett. 307:211–220. 2011. View Article : Google Scholar : PubMed/NCBI
5	Andrews PA and Howell SB: Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells. 2:35–43. 1990.PubMed/NCBI
6	Cho HJ, Kim JK, Kim KD, et al: Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett. 237:56–66. 2006. View Article : Google Scholar : PubMed/NCBI
7	Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
8	Kim VN and Nam JW: Genomics of microRNA. Trends Genet. 22:165–173. 2006. View Article : Google Scholar : PubMed/NCBI
9	Shyu AB, Wilkinson MF and van Hoof A: Messenger RNA regulation: to translate or to degrade. EMBO J. 27:471–481. 2008. View Article : Google Scholar : PubMed/NCBI
10	Iorio MV, Ferracin M, Liu CG, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
11	Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
12	Volinia S, Calin GA, Liu CG, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
13	Kovalchuk O, Filkowski J, Meservy J, et al: Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther. 7:2152–2159. 2008. View Article : Google Scholar : PubMed/NCBI
14	Nordentoft I, Birkenkamp-Demtroder K, Agerbæk M, et al: miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics. 5:402012. View Article : Google Scholar : PubMed/NCBI
15	Greenhough A, Smartt HJ, Moore AE, et al: The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 30:377–386. 2009. View Article : Google Scholar : PubMed/NCBI
16	Hasegawa K, Ishikawa K, Kawai S, et al: Overcoming paclitaxel resistance in uterine endometrial cancer using a COX-2 inhibitor. Oncol Rep. 30:2937–2944. 2013.PubMed/NCBI
17	Wu XL, Cheng B, Li PY, et al: MicroRNA-143 suppresses gastric cancer cell growth and induces apoptosis by targeting COX-2. World J Gastroenterol. 19:7758–7765. 2013. View Article : Google Scholar : PubMed/NCBI
18	He XP, Shao Y, Li XL, et al: Downregulation of miR-101 in gastric cancer correlates with cyclooxygenase-2 overexpression and tumor growth. FEBS J. 279:4201–4212. 2012. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
20	Xia L, Zhang D, Du R, et al: miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer. 123:372–379. 2008. View Article : Google Scholar : PubMed/NCBI
21	Srivastava SK, Tetsuka T, Daphna-Iken D and Morrison AR: IL-1 beta stabilizes COX II mRNA in renal mesangial cells: role of 3′-untranslated region. Am J Physiol. 267:F504–F508. 1994.PubMed/NCBI
22	Xiang KM and Li XR: MiR-133b acts as a tumor suppressor and negatively regulates TBPL1 in colorectal cancer cells. Asian Pac J Cancer Prev. 15:3767–3772. 2014. View Article : Google Scholar : PubMed/NCBI
23	Xu T, Zhou Q, Zhou J, et al: Carboxyl terminus of Hsp70-interacting protein (CHIP) contributes to human glioma oncogenesis. Cancer Sci. 102:959–966. 2011. View Article : Google Scholar : PubMed/NCBI
24	Kang JH, Song KH, Jeong KC, et al: Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells. BMC Cancer. 11:3342011. View Article : Google Scholar : PubMed/NCBI
25	Akutsu Y, Hanari N, Yusup G, et al: COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma. Ann Surg Oncol. 18:2946–2951. 2011. View Article : Google Scholar : PubMed/NCBI
26	Hong JH, Lee E, Hong J, Shin YJ and Ahn H: Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines. BJU Int. 90:113–117. 2002. View Article : Google Scholar : PubMed/NCBI
27	Friedman JM, Liang G, Liu CC, et al: The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res. 69:2623–2629. 2009. View Article : Google Scholar : PubMed/NCBI
28	Strillacci A, Griffoni C, Sansone P, et al: MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res. 315:1439–1447. 2009. View Article : Google Scholar : PubMed/NCBI
29	Varambally S, Cao Q, Mani RS, et al: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 322:1695–1699. 2008. View Article : Google Scholar : PubMed/NCBI
30	Zhang JG, Guo JF, Liu DL, Liu Q and Wang JJ: MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J Thorac Oncol. 6:671–678. 2011. View Article : Google Scholar : PubMed/NCBI
31	Wang HJ, Ruan HJ, He XJ, et al: MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer. 46:2295–2303. 2010. View Article : Google Scholar : PubMed/NCBI
32	Chen S, Wang H, Ng WL, Curran WJ and Wang Y: Radiosensitizing effects of ectopic miR-101 on non-small-cell lung cancer cells depend on the endogenous miR-101 level. Int J Radiat Oncol Biol Phys. 81:1524–1529. 2011. View Article : Google Scholar : PubMed/NCBI
33	Xu Y, An Y, Wang Y, et al: miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep. 29:2019–2024. 2013.PubMed/NCBI
34	Hwang MK, Kang NJ, Heo YS, Lee KW and Lee HJ: Fyn kinase is a direct molecular target of delphinidin for the inhibition of cyclooxygenase-2 expression induced by tumor necrosis factor-alpha. Biochem Pharmacol. 77:1213–1222. 2009. View Article : Google Scholar : PubMed/NCBI
35	Duffy CP, Elliott CJ, O’Connor RA, et al: Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer. 34:1250–1259. 1998. View Article : Google Scholar : PubMed/NCBI